Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Starton Therapeutics, Inc
- Target Recruit Count
- 6
- Registration Number
- NCT06087653
- Locations
- 🇺🇸
Gabrail Cancer & Research Center, Canton, Ohio, United States
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 182
- Registration Number
- NCT06084936
- Locations
- 🇫🇷
CHU NANTES - Hôtel Dieu, Nantes, France
🇧🇷ICTR Curitiba, Curitiba, Paraná, Brazil
🇨🇳Chongqing Cancer Hospital, Chongqing, China
Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma
- Conditions
- Relapsed/Refractory Marginal Zone Lymphoma
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 324
- Registration Number
- NCT06082102
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Auhui, China
🇨🇳Beijing Tongren Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Celgene
- Target Recruit Count
- 618
- Registration Number
- NCT06045806
- Locations
- 🇫🇷
Local Institution - 0082, Paris, France
🇬🇷Local Institution - 0061, Athens, Attikí, Greece
🇬🇷Local Institution - 0062, Chaidari, Attikí, Greece
MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Chest RadiographyProcedure: Computed TomographyProcedure: Low Dose Computed Tomography of the Whole BodyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyProcedure: X-Ray ImagingOther: Questionnaire Administration
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 100
- Registration Number
- NCT06042725
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- High Grade B-Cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Positron Emission Tomography
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT06015880
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸City of Hope Comprehensive Cancer Center LAO, Duarte, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RS
- Conditions
- Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 138
- Registration Number
- NCT06004765
- Locations
- 🇨🇳
Peking union medical college hospital, Beijing, China
A Study to Assess Safety and Efficacy of CHO-H01 As a Single Agent/Combined with Lenalidomide in Subjects with Refractory or Relapsed Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Cho Pharma Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT05950165
- Locations
- 🇨🇳
China Medical University Hospital - Hematology/Oncology - Taichung, Taichung City, Taiwan
🇨🇳National Cheng Kung University Hospital - Internal Medicine, Tainan, Taiwan
🇨🇳National Taiwan University Hospital - Hematology And Oncology, Taipei, Taiwan
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Refractory Mantle Cell LymphomaRecurrent Mantle Cell Lymphoma
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Lumbar PunctureProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2023-06-20
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 100
- Registration Number
- NCT05910801
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2023-08-14
- Target Recruit Count
- 35
- Registration Number
- NCT05900882
- Locations
- 🇨🇳
Nanjing First People's Hospital, Nanjing, Jiangsu, China
🇨🇳The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳Taizhou People's Hospital, Taizhou, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.